NASDAQ 100 Pre-Market Indicator Falls, ACRV Trades Over 23 Million Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 08 2026
0mins
Source: NASDAQ.COM
- Market Dynamics: The NASDAQ 100 Pre-Market Indicator decreased by 4.3 points to 25,649.6, indicating weakened market sentiment that could impact investor confidence and lead to increased volatility in the short term.
- ACRV Trading Activity: Acrivon Therapeutics, Inc. (ACRV) saw a pre-market trading volume of 23,307,591 shares, with a price drop of $0.06 to $2.89, reflecting high market interest but potential short-term pressure on the stock.
- TSLA and TQQQ Performance: Direxion Daily TSLA Bull 2X Shares (TSLL) and ProShares UltraPro QQQ (TQQQ) fell by $0.27 and $0.17 respectively, despite TQQQ's 214.29% increase from its 52-week low, indicating ongoing market uncertainty.
- VTYX and NVDA Recommendations: Ventyx Biosciences, Inc. (VTYX) and NVIDIA Corporation (NVDA) are both rated within the 'buy range', trading 2,195,689 shares and 2,158,778 shares respectively, demonstrating sustained investor interest in tech stocks.
Analyst Views on ACRV
Wall Street analysts forecast ACRV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACRV is 10.50 USD with a low forecast of 7.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.940
Low
7.00
Averages
10.50
High
19.00
Current: 1.940
Low
7.00
Averages
10.50
High
19.00
About ACRV
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. It uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
